ShangPharma opens pilot plant in Shanghai
For pharma development and cGMP manufacturing
The new multi-purpose pharmaceutical development and cGMP manufacturing facility will allow ShangPharma to support its clients Phase II and Phase III trials, expanding its service offering to include process and formulation r&d, analytical method development and validation, and cGMP manufacturing of intermediates and APIs.
Previously the CRO/CMO provided clients with materials for early discovery and GLP toxicology testing and Phase I clinical trials.
ShangPharma said it might further expand its manufacturing facilities if there is demand for commercial manufacturing of FDA- or EMEA-approved drugs.
The Fengxian facility will operate as a wholly owned subsidiary of the company under the name China Gateway Pharmaceutical Development Co. It includes a pilot plant that supports six separate bays with reactor capacities ranging from 200 to 3,000 litres and other speciality bays with reactor capacities ranging from 50 to 2000 litres for high temperature, cryogenics, highly toxic and pressurised reactions, including hydrogenation.
The company said there are also two cleanroom suites rated at Class 100,000 for isolation, 10 kilo-lab suites for bothnon-cGMP and cGMP manufacturing, as well as a large r&d laboratory for analytical, formulation and process development activities.
In addition, there are separate buildings for utilities, materials management, warehouse storage and waste water treatment with room for further expansion to support commercial manufacturing activities.
Testing of raw materials, intermediates and final products will be carried out at the site. An independent quality assurance department will ensure that materials are manufactured in accordance with cGMP requirements and that established standard operating procedures are followed, the firm said.
You may also like
Design & Build
The critical importance of BIM in cleanroom EPC projects
Read moreBuilding information modelling (BIM) represents the philosophy of building twice: first digitally, then physically. This proactive approach mitigates risk, controls costs and ensures that facilities meet critical performance criteria from day one
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
Design & Build
The critical importance of BIM in cleanroom EPC projects
Building information modelling (BIM) represents the philosophy of building twice: first digitally, then physically. This proactive approach mitigates risk, controls costs and ensures that facilities meet critical performance criteria from day one
Design & Build
EXCLUSIVE: Total Clean Air to launch modular pharma cleanroom brand with Vanguard Healthcare Solutions
Total Clean Air (TCA) will combine its cleanroom and containment expertise with Vanguard's renowned prefabrication to create an off-site fully compliant modular cleanroom for pharmaceutical, life science, and biotech applications